The Role of Aspirin as Otoprotective Agent in Patients Receiving Amikacin Therapy

Estabraq M. Mahdi Msc

Al-Kindy College Medical Journal مجلة كلية الطب الكندي
ISSN: 18109543 Year: 2011 Volume: 7 Issue: 1 Pages: 11-13
Publisher: Baghdad University جامعة بغداد


Objective: To investigate and prove that aspirinprotects, or at least attenuates amikacin ototoxicity inhumans.Method: This study was conducted in 60 patients thatcompleted allrequirements .The patients were divided into twogroups:• Control group: receive placebo treatment.• Drug–treated group: They receive aspirincoated tablets (1.5gm/ day), 500mg 8 hourly.Both groups had similar aspects regarding the gender,age and weight. The duration of therapy was 7 daysand dosage of amikacin was 1gm/day (500mg 12hourly).Results: Comparison of Audiometry test inEar/Nose/Throat (E.N.T.) Department (Pure ToneAudiometry) at 1000 Hertz (Hz), 2000 Hz, 4000 Hz,and 8000 Hz showed significant differences betweenmean Audiometry at 250Hz was significantly differentonly at 8th and 15th day while at the frequency of 500Hzthe difference was significant at the 15thday only.Conclusion: In present study, we had shown thataspirin can protect the patients who are receivingamikacin therapy from it' s ototoxicity.


Aspirin --- amikacin --- Pure Tone